Why the study?
Up to one-third of patients referred for TTVI have a transvalvular PPM or ICD lead, presenting complex decision-making regarding potential lead interactions, damage, or jailing.
Answers are grounded in this paper and cite their sources.
This scientific statement provides guidance on the complex management of patients with transvalvular RV leads undergoing transcatheter tricuspid valve interventions.
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI. Graphical abstract.
No takes yet. Share an insight, caveat, or question.
Deharo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: